Latest News

February 24, 2021

Aro Biotherapeutics Expands Leadership Team with Addition of Proven Scientific Executives

January 5, 2021

Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines

October 13, 2020

Aro Biotherapeutics Appoints Biotechnology Executive Dr. Christopher Mirabelli to its Board of Directors and Nucleic Acid Therapeutics Expert Dr. Masad Damha to its Scientific Advisory Board

October 6, 2020

Aro Collaboration with Ionis Advances with Option Exercise

February 11, 2020

Aro Biotherapeutics Appoints Leading Cancer Biologist Dr. Martin McMahon and Protein Structure and Design Expert Dr. Ronald Swanson to its Scientific Advisory Board

January 9, 2020

Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides